TD Cowen analyst Ritu Baral maintains $Sarepta Therapeutics (SRPT.US)$ with a buy rating, and maintains the target price at $203.
According to TipRanks data, the analyst has a success rate of 49.5% and a total average return of 14.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
Following Sarepta's announcement of an agreement with Arrowhead to license several clinical and preclinical programs, including a substantial upfront payment and equity investment, optimism around the deal is evident. This arrangement is seen enhancing Sarepta's pipeline, introducing more revenue possibilities beyond its main DMD franchise over the long term. It also aligns with the strategic goal to diversify beyond the initial focus on single-application gene therapies, addressing some investor concerns around the need for broader diversification.
The agreement with Arrowhead provides a diversified platform with a clear focus on long-term investment in strategies for rare chronic diseases and expands the therapeutic range to include muscle, central nervous system, and pulmonary indications. The alliance is strategically apt given Sarepta's expertise in rare genetic medicine, and the initiation of a share buyback program indicates a positive outlook on near-term revenue prospects.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
